Hydreight Updates on VSDHOne: Revolutionizing Direct-to-Consumer Healthcare Across All 50 States
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) has launched VSDHOne, a comprehensive Direct-to-Consumer healthcare platform now operational across all 50 U.S. states. The platform enables businesses to create their own healthcare brands with features including telemedicine technology, nationwide doctor networks, pharmacy fulfillment, and medical direction.
VSDHOne currently offers approximately 40 products across categories including skincare, hair loss, sexual health, hormone replacement therapy, and GLP-1 weight management. The platform operates on a SaaS model, with customers purchasing state-specific licenses and paying per-order fees. Since its Q2 2024 soft launch, VSDHOne has onboarded over 200 licenses and projects to reach 1,000 licenses by December 2025, with each license expected to process 5-20 orders daily.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) ha lanciato VSDHOne, una piattaforma di assistenza sanitaria Direct-to-Consumer ora operativa in tutti e 50 gli stati degli Stati Uniti. La piattaforma consente alle aziende di creare i propri marchi di assistenza sanitaria con funzionalità che includono tecnologia di telemedicina, reti di medici a livello nazionale, evasione di farmaci e direzione medica.
VSDHOne attualmente offre circa 40 prodotti in categorie che includono cura della pelle, perdita dei capelli, salute sessuale, terapia ormonale sostitutiva e gestione del peso GLP-1. La piattaforma opera su un modello SaaS, con clienti che acquistano licenze specifiche per stato e pagano commissioni per ordine. Dalla sua soft launch nel secondo trimestre del 2024, VSDHOne ha acquisito oltre 200 licenze e prevede di raggiungere 1.000 licenze entro dicembre 2025, con ogni licenza che si prevede elaborerà da 5 a 20 ordini al giorno.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) ha lanzado VSDHOne, una plataforma integral de atención médica Direct-to-Consumer que ya está operativa en los 50 estados de EE. UU. La plataforma permite a las empresas crear sus propias marcas de atención médica con características que incluyen tecnología de telemedicina, redes de médicos a nivel nacional, cumplimiento de farmacias y dirección médica.
VSDHOne actualmente ofrece aproximadamente 40 productos en categorías que incluyen cuidado de la piel, pérdida de cabello, salud sexual, terapia de reemplazo hormonal y gestión de peso GLP-1. La plataforma opera bajo un modelo SaaS, con los clientes comprando licencias específicas por estado y pagando tarifas por pedido. Desde su lanzamiento suave en el segundo trimestre de 2024, VSDHOne ha incorporado más de 200 licencias y proyecta alcanzar 1,000 licencias para diciembre de 2025, con cada licencia prevista para procesar de 5 a 20 pedidos diarios.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF)는 모든 주에서 운영되는 통합적인 소비자 직접 의료 플랫폼인 VSDHOne을 출시했습니다. 이 플랫폼은 기업이 원격 의료 기술, 전국적 의사 네트워크, 약국 충족 및 의료 지도를 포함한 기능으로 자신만의 의료 브랜드를 만들 수 있도록 합니다.
VSDHOne은 현재 피부 관리, 탈모, 성 건강, 호르몬 대체 요법 및 GLP-1 체중 관리와 같은 카테고리에서 약 40개의 제품을 제공합니다. 이 플랫폼은 SaaS 모델로 운영되며, 고객은 주별 면허를 구매하고 주문당 수수료를 지불합니다. 2024년 2분기 소프트 런칭 이후 VSDHOne은 200개 이상의 면허를 확보했으며, 2025년 12월까지 1,000개의 면허를 목표로 하고 있으며, 각 면허는 하루에 5-20개의 주문을 처리할 것으로 예상됩니다.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) a lancé VSDHOne, une plateforme de santé Direct-to-Consumer complète désormais opérationnelle dans les 50 États américains. La plateforme permet aux entreprises de créer leurs propres marques de santé avec des fonctionnalités telles que la technologie de télémedecine, des réseaux de médecins à l'échelle nationale, l'exécution des prescriptions et la direction médicale.
VSDHOne propose actuellement environ 40 produits dans des catégories telles que les soins de la peau, la perte de cheveux, la santé sexuelle, la thérapie de remplacement hormonal et la gestion du poids GLP-1. La plateforme fonctionne sur un modèle SaaS, les clients achetant des licences spécifiques aux États et payant des frais par commande. Depuis son lancement doux au cours du deuxième trimestre de 2024, VSDHOne a incorporé plus de 200 licences et prévoit d'atteindre 1 000 licences d'ici décembre 2025, chaque licence étant censée traiter de 5 à 20 commandes par jour.
Hydreight Technologies (TSXV: NURS, OTCQB: HYDTF) hat VSDHOne gestartet, eine umfassende Direct-to-Consumer-Gesundheitsplattform, die jetzt in allen 50 Bundesstaaten der USA operativ ist. Die Plattform ermöglicht es Unternehmen, eigene Gesundheitsmarken mit Funktionen wie Telemedizin-Technologie, landesweiten Ärztenetzwerken, Apothekerfüllung und medizinischer Leitung zu erstellen.
VSDHOne bietet derzeit etwa 40 Produkte in Kategorien wie Hautpflege, Haarausfall, sexuelle Gesundheit, Hormontherapie und GLP-1 Gewichtskontrolle an. Die Plattform arbeitet nach einem SaaS-Modell, bei dem Kunden landesspezifische Lizenzen erwerben und pro Bestellung Gebühren zahlen. Seit dem Soft-Launch im 2. Quartal 2024 hat VSDHOne über 200 Lizenzen gewonnen und plant, bis Dezember 2025 insgesamt 1.000 Lizenzen zu erreichen, wobei jede Lizenz täglich 5-20 Bestellungen verarbeiten soll.
- Platform already operational in all 50 states
- Over 200 licenses onboarded since Q2 2024 soft launch
- Projected growth to 1,000 licenses by December 2025
- Recurring revenue model through SaaS and per-order fees
- Each license expected to process 5-20 orders daily
- No current revenue figures provided
- Market guidance delayed until end of Q1
VANCOUVER, British Columbia and LAS VEGAS, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight”or the “Company”)(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a fast-growing mobile clinical network and medical platform which enables flexible at-home medical services across 50 states in the United States, is providing an update on VSDHOne, its Direct-to-Consumer (D2C) healthcare platform. Now fully operational in all 50 states, VSDHOne is redefining telehealth by offering businesses an unparalleled, end-to-end solution to launch their own healthcare brands—quickly, cost-effectively, and at scale.
What is VSDHOne?
VSDHOne provides a comprehensive telemedicine platform that empowers businesses, including MedSpas, health and wellness entrepreneurs, retailers, and pharmaceutical brands, to create D2C healthcare solutions in days rather than months. The purpose of launching VSDHOne is to make it easy for any existing brick and mortar or individuals to launch a direct to consumer healthcare brand in a few weeks without worrying about compliance, doctor network, telemedicine and ecommerce Technology, Medical direction and oversight, Pharmacy network, and a medical legal framework in all 50 States.
With the marriage of Virtual and at facility healthcare features, Companies can expand beyond their current Bricks and Mortar solutions.
Features include:
- eCommerce Platform
- Telemedicine Technology
- Booking and Scheduling Technology
- Nationwide Doctors Network in all 50 States
- Pharmacy Network and fulfillment partners
- Medical Direction
- Medical Legal Structure
- Payment Processing
- LegitScript approved - Enterprise Partner
- Affiliate Marketing Automation
“VSDHOne bridges the gap in healthcare accessibility, empowering nontraditional players to deliver personalized, convenient care directly to consumers. This isn’t just telemedicine; it’s Telehealth 2.0,” said Shane Madden, CEO, Hydreight Technologies.
Available Treatments on the platform:
There are currently about 40 products available on the platform for the clients to offer to their patients. VSDHOne supports a wide range of treatments tailored to meet growing consumer demand for convenient, personalized care. The platform currently offers:
- Skincare Treatments: Including acne and anti-aging solutions.
- Hair Loss Treatments: Clinically-backed therapies to promote hair regrowth.
- Sexual Health: Addressing common concerns with effective, discreet care.
- Hormone Replacement Therapy: Including Sermorelin and Testosterone Replacement Therapy (TRT).
- GLP-1 Weight Management: Cutting-edge treatments for obesity and weight management.
- Peptides
Future Treatments Coming to the Platform
Hydreight continues to expand VSDHOne’s offerings to include innovative therapies:
- Genetic Testing
- Birth Control Options
- Oral GLP-1 Therapies
- NAD+ Nasal Spray for anti-aging and energy
- Longevity-focused solutions
These treatments position VSDHOne as a comprehensive solution for a wide array of consumer healthcare needs, creating opportunities for businesses to grow their offerings and drive recurring patient engagement.
Current Market and Its Gaps:
Consumer trust in the healthcare system is at an all-time low. This is due to equal access to care and pricing. In certain states, there remains a significant limitation in accessing healthcare professionals. More than
Since the COVID-19 pandemic, the demand for telemedicine has surged, with adoption rates among physicians rising from
There are many online providers for these treatments but they either are using different providers for different needs or they may not follow the best practices to have the full compliance. VSDHOne empowers providers from online providers, health clubs to existing brick and mortar locations to expand their offerings to consumers directly without being worried about the medical operational side of the offerings. They place a widget on their website and as soon as a patient lands on their website, they will go through the VSDHOne widget step by step platform and will receive their treatments and medications.
A Compelling Business Model:
VSDHOne operates on a SaaS-based model, with customers purchasing state-specific licenses and paying per-order fees for the platform’s end-to-end capabilities. This provides Hydreight with a recurring revenue stream while offering clients unparalleled scalability.
Since its soft launch in late Q2 2024, VSDHOne has been onboarding over 200 licenses, far exceeding expectations. The platform and management projects to have over 1,000 licenses by December 2025, creating significant recurring revenue opportunities.
VSDHOne team is projecting each license to process approximately between 5 to 20 orders per day after full onboarding. The company will aim to provide guidance to the market by the end of Q1 after fully onboarding the first group of licenses and monitoring their traction in the first months. Most of the orders and treatments are ongoing treatments that patients need to have follow up orders every month after the initial month.
“Hims & Hers Health, Inc. reported that it processed approximately 2.66 million net orders with an Average Order Value (“AOV”) of approximately
WEBINAR:
The Company’s management, and Medical team will be hosting a webinar to discuss more details about this in January 2025.
For more information or to get started, please email business@vsdigitalhealth.com.
About VSDHOne - Direct to Consumer Platform
In a partnership with two other parties, Hydreight Technologies launched the VSDHOne (Read as VSDH-One)platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s (semaglutide, tirzepatide), peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more.
Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
About Hydreight Technologies Inc.
Hydreight Technologies Inc. is building one of the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Contact
Email: ir@hydreight.com; Telephone: 1 (702) 970-8112
This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, path to profitability, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “projecting”, “expect” or similar expressions and includes information regarding expectations for the Company's growth, VSDHone’s number of licenses and orders in 2025.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
FAQ
How many licenses has VSDHOne secured since its Q2 2024 launch for HYDTF stock?
What is the projected number of licenses for HYDTF's VSDHOne platform by December 2025?
How many daily orders is each VSDHOne license expected to process for HYDTF?
What treatment categories does HYDTF's VSDHOne platform currently offer?
When will HYDTF provide market guidance for VSDHOne performance?
